FDA OKs Kcentra as antidote to warfarin

04/30/2013 | Los Angeles Times (tiered subscription model)

The FDA has approved the prothrombin complex concentrate Kcentra as a reversal agent for the anticoagulant warfarin. Health care providers will not need to match Kcentra with a patient's blood type, so it can be used faster than plasma to reverse the effects of warfarin. It cannot be used to reverse the effects of newer anticoagulants dabigatran and rivaroxaban.

View Full Article in:

Los Angeles Times (tiered subscription model)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
MEDICAL SCIENCE LIAISON - 14000002RO
Abbott
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Executive Medical Director
Aspirus Network Inc
Wausau, WI